STOCK TITAN

Akebia Therapeutics (AKBA) director receives RSU and stock option grants

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Akebia Therapeutics director Leanne M. Zumwalt received equity awards in the form of common stock and stock options. She was granted 35,700 shares of Common Stock as restricted stock units under Akebia’s 2023 Stock Incentive Plan, bringing her direct common stock holdings to 145,100 shares after the grant.

She was also granted a stock option for 53,600 shares of common stock with an exercise price of $1.02 per share, expiring on June 17, 2036. Both the RSUs and the option vest 100% on the first anniversary of the grant date, or earlier immediately before the first annual meeting of stockholders after the grant, if she continues serving the company.

Positive

  • None.

Negative

  • None.
Insider ZUMWALT LEANNE M
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to buy) 53,600 $0.00 $0.00
Grant/Award Common Stock 35,700 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to buy) — 53,600 shares (Direct); Common Stock — 145,100 shares (Direct)
Footnotes (2)
  1. F1. The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
  2. F2. The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
RSU grant 35,700 shares Restricted stock units granted June 17, 2026
Option grant size 53,600 shares Stock option covering common stock granted June 17, 2026
Option exercise price $1.02 per share Conversion or exercise price of stock option
Option expiration June 17, 2036 Expiration date of stock option grant
Shares owned after grant 145,100 shares Total common stock directly held following RSU grant
RSU vesting schedule 100% after one year Vests on first anniversary or before next annual meeting
restricted stock units financial
"The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2023 Stock Incentive Plan financial
"were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan")"
Non-Employee Director Compensation Program financial
"as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program")"
Stock Option financial
"The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity awards did Akebia (AKBA) director Leanne Zumwalt receive?

Leanne Zumwalt received 35,700 restricted stock units and a stock option covering 53,600 shares of Akebia common stock. Both awards were granted under the 2023 Stock Incentive Plan as part of the company’s non-employee director compensation program.

How do the new grants affect Leanne Zumwalt’s AKBA share holdings?

After the grant of 35,700 restricted stock units, Leanne Zumwalt directly holds 145,100 shares of Akebia common stock. She also holds a new stock option for 53,600 shares, which is an additional potential equity position subject to future vesting and exercise.

When do Leanne Zumwalt’s new Akebia RSUs and options vest?

Both the 35,700 restricted stock units and the 53,600-share stock option vest 100% on the first anniversary of the June 17, 2026 grant date. Vesting may occur earlier, immediately before the first annual stockholder meeting after grant, if she continues serving Akebia.

What is the exercise price and term of Leanne Zumwalt’s AKBA stock option?

The new stock option granted to Leanne Zumwalt allows purchase of 53,600 Akebia common shares at an exercise price of $1.02 per share. The option expires on June 17, 2036, assuming it vests and remains outstanding under the plan’s terms.

Are Leanne Zumwalt’s recent AKBA transactions open-market purchases?

No, the reported acquisitions are equity grants, not open-market purchases. She received 35,700 restricted stock units and a 53,600-share stock option at no purchase price, granted under Akebia’s 2023 Stock Incentive Plan for non-employee directors.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ZUMWALT LEANNE M

(Last)(First)(Middle)
C/O AKEBIA THERAPEUTICS, INC.
245 FIRST ST.

(Street)
CAMBRIDGE MASSACHUSETTS 02142

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Akebia Therapeutics, Inc. [ AKBA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/17/2026A35,700(1)A$0.00145,100D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to buy)$1.0206/17/2026A53,60006/17/2027(2)06/17/2036Common Stock53,600$0.0053,600D
Explanation of Responses:
1. The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
2. The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Remarks:
/s / Carolyn Rucci, attorney-in-fact for LeAnne M. Zumwalt06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)